Journal Club
-
Upload
nick-gowen -
Category
Health & Medicine
-
view
607 -
download
4
description
Transcript of Journal Club
![Page 1: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/1.jpg)
G U R U S U B R A M A N I A N G U R U M U R T H Y M D
P G Y - 3
I N T E R N A L M E D I C I N E
CHRONIC LYMPHOCYTIC LEUKEMIA“TOWARDS A NEW ERA IN THE MANAGEMENT”
![Page 2: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/2.jpg)
Chronic Lymphocytic Leukemia
Indolent B-cell neoplasm characterized by the clonalproliferation and accumulation of mature, typically CD5-positive B-cells within the blood, bone marrow, lymph nodes, and spleen.
![Page 3: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/3.jpg)
Epidemiology
Most common leukemia in the western world.
Age-adjusted incidence of 4.1/100,000 in the United States
Median age at diagnosis lies between 67 and 72 years.
More male than female patients (1.7:1)
![Page 4: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/4.jpg)
Clinical Features
Around 25% of patients are asymptomatic
Constitutional: night sweats, fever, weakness, weight loss
Recurrent infections (bacterial, viral – Herpes Zoster, fungal)
Bleeding manifestations due to thrombocytopenia
Lymphadenopathy
Splenomegaly
Hepatomegaly
Autoimmune anemia and thrombocytopenia, PRCA.
Hypogammaglobulinemia
MPGN as a paraneoplastic manifestation
![Page 5: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/5.jpg)
Diagnosis
Absolute B-lymphocyte count ≥ 5 x 10 9/L in the peripheral blood.
Clonality of the circulating B-lymphocytes needs to be confirmed by flow cytometry.
Small, mature lymphocytes positive for CD5, CD19, CD20, and CD23. The levels of surface immunoglobulin (Ig) are characteristically low compared to those found on normal B cells
![Page 6: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/6.jpg)
Lymphocytosis and Smudge Cells
![Page 7: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/7.jpg)
Staging
![Page 8: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/8.jpg)
Staging
![Page 9: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/9.jpg)
Chromosomal abnormalities in CLL
del(13q14) occurring in approx. 55%
del(11q) in 25% of chemotherapy-naïve
Trisomy 12 in 10–20% of patients
del(17p) in 5–8% of chemotherapy-naive patients. Show marked resistance against chemotherapies.
![Page 10: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/10.jpg)
When to Treat CLL Patients
No advantage to treating CLL until symptoms develop irrespective of genomic features
IWCLL 2008 criteria for treatment
o Enlarging, symptomatic lymph nodes (> 10 cm)
o Enlarging, symptomatic spleen (> 6 cm)
o Cytopenias due to CLL (hemoglobin < 11, platelets < 100)
o Constitutional symptoms due to disease (fatigue, B symptoms)
o Poorly controlled AIHA or ITP
o Lymphocyte doubling time < 6 months or increase of 50% over a 2-month time period
![Page 11: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/11.jpg)
History of CLL Therapy
Chlorambucil:
- well tolerated oral agent but low response
Fludarabine
- Higher response, longer remission but no major impact on survival; not beneficial to age >65 years
Fludarabine/cyclophosphamide
- Higher response, longer remission, but no major impact on survival
Antibody rituximab:
- well tolerated with low response
Rituximab addition to fludarabine ± cyclophosphamide(FCR):
- higher response, longer remission and overall survival .
![Page 12: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/12.jpg)
CLL Therapy
FCR currently standard therapy for younger CLL patients
Bendamustine + Rituximab often substituted for FCR
Older patients (age > 65) are treated with chlorambucil/Rituximab or Bendamustine + Rituximab
![Page 13: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/13.jpg)
How long do these therapies work ?
Six-year follow-up is available for 300 patients initially treated with FCR combination therapy as part of prospective phase II trials.
Six-year overall and failure-free survival rates were 77 and 51 percent, respectively, and the median time to progression was 80 months.
![Page 14: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/14.jpg)
Relapse
Invariably occurs in all patients after stopping therapy.
Interval from last treatment to onset of relapse is important in determining the choice of further therapy.
Progressive disease occurring more than 12 months after the discontinuation of treatment can be retreated using the same medication, or by switching to other available treatments.
Relapse within 12 months or disease refractoriness would necessitate usage of alternative strategies.
![Page 15: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/15.jpg)
Salvage therapy options for relapse
Fludarabine, Cyclophosphamide, and Rituximab
Bendamustine + Rituximab
High dose Solumedrol + Rituximab
Lenalidomide ± Rituximab
Ofatumumab—58% response but short PFS
Idelalisib
Alemtuzumab
Allogeneic stem cell transplantation
![Page 16: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/16.jpg)
Difficult to treat groups
Short duration of response to initial therapy
Adverse cytogenetic abnormalities such as del 17p
Refractory CLL
![Page 17: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/17.jpg)
B cell Receptor Signaling
![Page 18: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/18.jpg)
Ibrutinib
Ibrutinib is a first-in-class, oral covalent inhibitor of Bruton’s tyrosine kinase, an essential enzyme in B-cell receptor signaling, homing, and adhesion.
Blocks survival signals transmitted from the microenvironment to CLL tumor cells through the B cell receptor signaling pathway
Phase 2 studies in relapsed or refractory CLL showed a response rate of 71%
FDA approved for CLL (in February 2014) who had received at least one previous therapy.
![Page 19: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/19.jpg)
J O H N C . B Y R D , M . D . , J E N N I F E R R . B R O W N , M . D . , P H . D . , S U S A N O ' B R I E N , M . D E T A L .
N E N G L J M E D
V O L U M E 3 7 1 ( 3 ) : 2 1 3 - 2 2 3
J U L Y 1 7 , 2 0 1 4
Ibrutinib versus Ofatumumab in Previously Treated Chronic
Lymphoid Leukemia
![Page 20: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/20.jpg)
Background
On the basis of the phase 2 trial, a multicenter, open-label, randomized, phase 3 trial was initiated -Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (RESONATE)
![Page 21: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/21.jpg)
Overview
Period - June 2012 through April 2013
67 sites in the United States, Australia, and seven European countries.
Funded by Pharmacyclics and Janssen;
RESONATE ClinicalTrials.gov number NCT01578707.
![Page 22: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/22.jpg)
Eligibility Criteria
![Page 23: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/23.jpg)
Additional criteria
ECOG performance status of less than 2
Absolute neutrophil count of at least 750 cells per microliter
Platelet count of at least 30,000 cells per microliter
Adequate liver and kidney function.
![Page 24: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/24.jpg)
Exclusion Criteria
Patients requiring warfarin or strong CYP3A4/5 inhibitors were excluded
Patients who did not meet the inclusion criteria
![Page 25: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/25.jpg)
Therapy
Patients were randomly assigned to receive either
Oral ibrutinib at a dose of 420 mg once daily until disease progression or the occurrence of unacceptable toxic effects OR
Intravenous ofatumumab for up to 24 weeks at an initial dose of 300 mg at week 1, followed by a dose of 2000 mg weekly for 7 weeks and then every 4 weeks for 16 weeks.
![Page 26: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/26.jpg)
![Page 27: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/27.jpg)
End points
Primary end point - duration of progression-free survival, according to the criteria of the International Workshop on Chronic Lymphocytic Leukemia.
Secondary end points included the duration of overall survival and the response rate.
![Page 28: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/28.jpg)
![Page 29: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/29.jpg)
Followup
Patients were monitored weekly for the first 8 weeks, every 4 weeks until month 6, and then every 12 weeks, with full response assessments performed every 12 weeks.
CT to evaluate response and persistent improvement for at least 2 months to confirm response
![Page 30: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/30.jpg)
Statistics
Primary analysis was a two-sided log-rank test stratified according to the presence or absence of the chromosome 17p13.1 deletion and the disease refractory status at randomization.
Type I error was controlled through adjustment of the significance level with the use of the O’Brien–Fleming boundary for the interim analysis
Hierarchical closed-testing procedure for primary and ordered secondary end points.
![Page 31: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/31.jpg)
Results
![Page 32: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/32.jpg)
PFS and OS
At a median follow-up of 9.4 months, ibrutinib significantly improved PFS.
Median duration was not reached in the ibrutinib group (PFS of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab group (hazard ratio in the ibrutinib group, 0.22; P<0.001).
Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P = 0.005). At 12 months, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group.
Overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P<0.001).
![Page 33: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/33.jpg)
17p deletion cohort
Median duration of progression-free survival was not reached in the ibrutinib group, as compared with a median of 5.8 months in the ofatumumab group (hazard ratio 0.25; 95% CI, 0.14 to 0.45).
At 6 months, 83% of the patients in the ibrutinibgroup, as compared with 49% of those with this deletion in the ofatumumab group, were alive with no disease progression.
![Page 34: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/34.jpg)
Overall Survival
57 patients in the ofatumumab group had crossed over to receive ibrutinib after confirmed disease progression.
Survival effect was based on an analysis in which data were censored at the time of crossover.
At 12 months, the survival effect was also observed in the uncensored sensitivity analysis (hazard ratio 0.39; P = 0.001), with an overall survival rate of 90% in the ibrutinib group and 79% in the ofatumumab group
![Page 35: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/35.jpg)
OS and PFS
![Page 36: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/36.jpg)
Subgroup Analyses of Progression-free Survival
![Page 37: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/37.jpg)
Overall Survival
![Page 38: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/38.jpg)
Adverse Reactions
The most frequent non-hematologic adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group.
Slightly higher incidence of AF, visual blurring and minor skin bleeds in ibrutinib group.
![Page 39: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/39.jpg)
Adverse events
![Page 40: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/40.jpg)
Conclusions
Ibrutinib significantly improves the overall response, PFS and OS as compared to ofatumumab in previously treated CLL patients.
![Page 41: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/41.jpg)
Strengths
Phase III randomized study
Included the group of patients in whom the common treatment options did not work, hence addressed an unmet need.
Changes the landscape of CLL therapy
![Page 42: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/42.jpg)
Weakness
Short follow-up period.
Did not include patients with poor performance status, liver dysfunction, renal dysfunction, and patients on warfarin.
Comparison against a new monotherapy
![Page 43: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/43.jpg)
Future directions
Combination of Ibrutinib with other chemotherapy regimens
Role of ibrutinib in treatment naïve patients.
![Page 44: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/44.jpg)
Points for Internists
Be aware of the side effects
Lymphocytosis during initial phase of treatment is common.
Not tested in patients taking warfarin.
Need to hold the drug before and after any elective surgical procedure with bleeding risk (1 week before and after).
![Page 45: Journal Club](https://reader033.fdocuments.in/reader033/viewer/2022042614/559b28391a28ab921c8b45b9/html5/thumbnails/45.jpg)
References
Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446.
Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112:975.
Uptodate – Chronic lymphocytic leukemia.